HONG KONG – Taiwan-U.S. biopharma company Foresee Pharmaceutical Co. Ltd. has out-licensed its core asset FP-001 (leuprorelin depot) for treating prostate cancer to U.K.-based Accord Healthcare in an $86 million deal.
HONG KONG – Shanghai Haihe Biopharma Co. Ltd. has completed a series B financing, raising $144.6 million. Added to a prior round that secured about $50 million, Eric He, chief business officer at Haihe, told BioWorld Asia, the firm plans to use the funds to move forward its 10 clinical assets and five preclinical candidates for antineoplastic and metabolic diseases.
HONG KONG – Shanghai Haihe Biopharma Co. Ltd. has completed a series B financing, raising $144.6 million. Added to a prior round that secured about $50 million, Eric He, chief business officer at Haihe, told BioWorld, the firm plans to use the funds to move forward its 10 clinical assets and five preclinical candidates for antineoplastic and metabolic diseases.
HONG KONG – China's Ascletis Pharma Inc. and California-based 3-V Biosciences Inc. have inked a licensing deal for 3-V Biosciences' fatty acid synthase (FASN) inhibitor TVB-2640.
HONG KONG – Taiwan-U.S. biopharma company Foresee Pharmaceutical Co. Ltd. has out-licensed its core asset FP-001 (leuprorelin depot) for treating prostate cancer to U.K.-based Accord Healthcare in an $86 million deal.
HONG KONG – When it comes to innovation in China, the largest companies top the rankings. The annual Clarivate Analytics Top 100 Chinese Innovators list was dominated by big conglomerates such as Fosun International Ltd. and China Resources (Holdings) Co. Ltd. Travis Hu, general manager of Clarivate Life Sciences Business for greater China, said that big corporations have certain given advantages when it comes to drug discovery.
HONG KONG – Chinese drug regulators have granted the first marketing clearance to a homegrown dipeptidyl peptidase-4 (DPP-4) inhibitor for treating type 2 diabetes, developed by Jiangsu Aosaikang Pharmaceutical Co. Ltd. The saxagliptin tablet, which comes in 5 mg or 2.5 mg, is registered as a category IV chemical drug – a generic with equivalent quality and efficacy to the originator's drugs that are already marketed in China.
HONG KONG – Chinese drug regulators have granted the first marketing clearance to a homegrown dipeptidyl peptidase-4 (DPP-4) inhibitor for treating type 2 diabetes, developed by Jiangsu Aosaikang Pharmaceutical Co. Ltd. The saxagliptin tablet, which comes in 5 mg or 2.5 mg, is registered as a category IV chemical drug – a generic with equivalent quality and efficacy to the originator's drugs that are already marketed in China.
